Getinge Group: Getinge Has Secured over 75 % of the Outstanding Shares in Pulsion ­ and the Transaction Has Been Approved by German Federal Cartel Office

Regulatory News:

As earlier communicated, Getinge (STO:GETIB) has issued a public tender offer to acquire all shares in Pulsion Medical Systems SE ("Pulsion”) listed on the German Stock Exchange (Deutsche Börse) for an offer price of € 16.90 per share in cash.

Getinge has now secured 76.88% of the outstanding shares and voting rights in Pulsion, which corresponds to 6.342.945 shares. In addition, the German Federal Cartel Office (Bundeskartellamt) has approved the transaction, today.

The board of Pulsion has recommended the Pulsion shareholders to accept the public tender offer.

The acceptance period is still ongoing and will expire on 12 February 2014. The transaction is expected to be completed in the first quarter of 2014.

Further conditions and information pertaining to the public tender offer are set forth in the offer document and is available on www.maquet.com/pulsion-angebot.

Disclaimer

The public tender offer is inter alia subject to the condition that a minimum acceptance threshold of at least 75% of the Pulsion shares (including shares owned by the offeror and persons/companies acting jointly with the offeror) is reached. The condition of the minimum acceptance threshold is defined in the offer document to the effect, that the condition cannot be met before expiry of the offer period. Thus, this condition has not yet been fulfilled even though the current acceptance level exceeds 75%.

GETINGE GROUP is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and MAQUET. ArjoHuntleigh focuses on patient mobility and wound management solutions. GETINGE provides solutions for infection control within healthcare and contamination prevention within life sciences. MAQUET specializes in solutions, therapies and products for surgical interventions, interventional cardiology and intensive care. The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act

This information was brought to you by Cision